EN DE
Watch Curvebeam Ai Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Curvebeam Ai Ltd (CVB) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Curvebeam Ai Ltd stock A$0.02, price A$0.02, upside +2.2%, quality 21 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · Based in US · ISIN AU0000289761

CA Curvebeam Ai Ltd logo Thin data Nov 10, 2026

Curvebeam Ai Ltd

CVB · AU
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value A$0.0184 · Fairly valued
Mixed Growth (revenue 5y +3.8 %/yr in AUD)
Moderate debt
Revenue last quarter 49% below a year ago.
Quality 21/100
Negative free cash flow
Trails peers (2/7)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Curvebeam Ai Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.5000 A$0.0150 Fair Value A$0.0184 Aug 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

39‑month range A$0.0150 – A$0.5000 · fair‑value band A$0.0175 – A$0.0193 · the A$0.0180 price screens below the A$0.0184 fair value. As of Nov 10, 2026.

Follow Curvebeam Ai in your weekly email

Every Wednesday you see whether Curvebeam Ai is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and Australia.

Show moreShow less

The company offers HiRise for bilateral weight bearing CT imaging; LineUP, a bilateral, weight bearing CT imaging of the knees and lower extremities for orthpedic practices; pedCAT Premium and pedCAT for imaging of the foot and ankle; InReach, a point-of-care extremity CT imaging which assess the distal extremities with 3D clarity at a fraction of the dose; and CubeVue Software visualization tools.

It also provides software CurveBeam AI Autometrics for automatically segment foot and ankle datasets; Axiometrics, provides a semi-automatic measurement of the axes of rotation of the hip, femur, knee, and ankle; and TALAS, a measurement tool that semi-automatically calculate hindfoot alignment based on reproducible three-dimensional anatomical landmarks.

In addition, the company offers custom web-based cloud platform; and OSSView. The company was incorporated in 2009 and is headquartered in Hatfield, Pennsylvania.

Stock analysis

Curvebeam Ai Ltd (CVB) currently trades at A$0.0180, while our estimate is A$0.0184, so the stock looks roughly fairly valued today (gap 2.2%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0175 (bear) to A$0.0193 (bull), the price of A$0.0180 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Curvebeam Ai Ltd reported revenue of A$8.7M in FY2026 versus A$1.7M in FY2022, a compound +50.9%/yr. Reported net income was −A$18.8M in FY2026.

Key figures

Market cap A$8.6M (≈ $5.9M) Micro · P/S ratio 0.76 · EPS (TTM) A$−0.0400 · Return on equity −59.9% · Return on assets (EBIT) −46.8% (4-year average) · Operating margin −219% · Revenue (TTM) A$8.7M · Revenue growth (YoY) −48.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 80% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at 2%, CVB screens richer than that median.

Fair Value

Bear A$0.0175 Fair Value A$0.0184 Bull A$0.0193
Price A$0.0180 · Upside +2.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 21/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 6
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 40
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 3
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−28.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2021 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−105.9% (2021) → −235.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch CVB, get fair value alerts →

Compare Curvebeam Ai Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside +2.2% · Above median
Profitability
Return on assets −35.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −48.5% · Bottom 25%
Balance sheet
Debt / equity 0.53× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.31× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.99× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)36 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)73 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs CVB
DexCom, Inc DXCM $79.92 $89.18 +12% vs CVB
Stryker Corporation SYK $324.29 $358.30 +10% vs CVB
STERIS plc STE $257.12 $279.53 +9% vs CVB
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs CVB
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs CVB
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs CVB
Abbott Laboratories, ABT $110.46 $75.28 −32% vs CVB
Medtronic plc MDT $101.59 $65.61 −35% vs CVB
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs CVB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Curvebeam Ai Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Curvebeam Ai Ltd Fair Value". https://www.fairvalue-calculator.com/stock/CVB

Frequently asked questions

Is Curvebeam Ai Ltd (CVB) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0184 versus a price of A$0.0180, about +2% upside (fairly valued).
What is the fair value of CVB?
Our estimate for Curvebeam Ai Ltd is A$0.0184 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0180.
What is the quality score of CVB?
Curvebeam Ai Ltd has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Curvebeam Ai Ltd (CVB)?
Our calculated price target is the estimate of A$0.0184 (as of Nov 10, 2026). Cautious scenario A$0.0175, optimistic scenario A$0.0193. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Curvebeam Ai Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.0184, about +2% upside versus a price of A$0.0180 (fairly valued). Cautious scenario A$0.0175, optimistic scenario A$0.0193. The calculation is refreshed regularly with new filings.
What is the revenue of Curvebeam Ai Ltd (CVB)?
Curvebeam Ai Ltd reported trailing-twelve-month revenue of about A$8.7M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Curvebeam Ai Ltd (CVB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Curvebeam Ai Ltd it is A$0.0184 per share (as of Nov 10, 2026), against a price of A$0.0180.
Is Curvebeam Ai Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CVB trades below its calculated fair value: price A$0.0180, fair value A$0.0184, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CVB?
No. The price is what the market pays today (A$0.0180); the fair value is what the company's own numbers justify (A$0.0184). For Curvebeam Ai Ltd the two are A$0.0004 per share apart. That gap is exactly why we show both numbers side by side.
How much is Curvebeam Ai Ltd worth?
The market values Curvebeam Ai Ltd at about A$8.6M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0180; our models calculate a fair value of A$0.0184 per share.
What do the bullish and bearish scenarios say about CVB?
Our models span a range for Curvebeam Ai Ltd: cautious scenario A$0.0175, base A$0.0184, optimistic A$0.0193 per share (as of Nov 10, 2026, price A$0.0180). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Curvebeam Ai Ltd (CVB)?
Balance-sheet figures for Curvebeam Ai Ltd (as of Nov 10, 2026): return on equity −59.9%, debt of 0.53 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is CVB from its 52-week high?
Curvebeam Ai Ltd trades at A$0.0180, about 80% below its 52-week high of A$0.0910 and 20% above the low of A$0.0150 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0184 is for.
Which stocks are comparable to Curvebeam Ai Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Curvebeam Ai Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0180, calculated fair value A$0.0184 (+2%), Quality Score 21/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Curvebeam Ai Ltd currently trades 2% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Curvebeam Ai Ltd (CVB)?
The closing price on Nov 11, 2026 was A$0.0180. Our estimate is A$0.0184, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Curvebeam Ai Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (A$0.0175 to A$0.0193), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Curvebeam Ai Ltd

How large is the market capitalisation of Curvebeam Ai Ltd (CVB)?
The market capitalisation of Curvebeam Ai Ltd is A$8.6M (≈ $5.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Curvebeam Ai Ltd (CVB)?
The price-to-sales ratio of Curvebeam Ai Ltd is 0.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Curvebeam Ai Ltd (CVB)?
Earnings per share at Curvebeam Ai Ltd are A$−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Curvebeam Ai Ltd (CVB)?
The return on equity (ROE) of Curvebeam Ai Ltd is −59.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Curvebeam Ai Ltd (CVB)?
On an EBIT basis the return on assets of Curvebeam Ai Ltd is −46.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Curvebeam Ai Ltd (CVB)?
The operating margin of Curvebeam Ai Ltd is −219% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Curvebeam Ai Ltd (CVB)?
Revenue at Curvebeam Ai Ltd is growing −48.5% versus a year earlier (3y avg +2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Curvebeam Ai Ltd (CVB) generate?
The free cash flow of Curvebeam Ai Ltd is −A$13.0M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Curvebeam Ai Ltd (CVB) carry?
The net debt of Curvebeam Ai Ltd is A$14.5M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Curvebeam Ai Ltd in the live analysis

One click puts Curvebeam Ai Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.